MM-111, a bispecific HER2/HER3 antibody, reduced HER2/3-PI3K signaling, suppressed HER2-positive xenograft tumor growth, and showed synergy with trastuzumab or lapatinib against HER2-positive breast cancers in vivo [159]. The gene discussed is PIK3CA; the disease is breast cancer.